RARE Looks 68.1% Undervalued on GF Value™ After FDA Approval Boo
Ultragenyx (RARE) received FDA approval for its gene therapy Fayuvi, the first treatment for Type A Sanfilippo syndrome. The company's P/S ratio is 2.09, below its historical median of 16.1x. GuruFocus estimates RARE is 68.1% undervalued at $14.50 per share, but notes risks due to ongoing losses and cash burn. Insiders have sold $4.0M in shares in the past year.
How this was made
The 30-second read
Why it matters
The FDA approval creates a new commercial product, potentially improving cash flow and valuation metrics.
Market read
A rare‑disease biotech receives a landmark approval, likely prompting short‑term buying pressure and sector uplift.
What to watch
Potential reimbursement challenges and competition from emerging gene‑editing platforms.
Background
Ultragenyx focuses on ultra‑rare genetic diseases; prior products include Crysvita and Evkeeza.
Ticker impact
Ultragenyx (RARE) received full FDA approval for its gene therapy Fayuvi (UX111) for pediatric Sanfilippo type A, a first‑in‑class treatment.
Potential upside of 10‑15% over the next weeks as investors price in the new product.
First FDA approval for a rare disease therapy, priority review voucher awarded, and existing market skepticism may be corrected.
Market effects
Boosts sentiment for rare‑disease biotech peers and may lift sector ETFs.
Positive for US biotech market; limited immediate effect elsewhere.
Highlights US regulatory advantage for gene‑therapy developers worldwide.
Counterpoint
Insider selling and weak balance sheet suggest execution risk; price may be overstated.
Key entities
- CompanyUltragenyx Pharmaceutical Inc
Developer of Fayuvi (UX111) and other rare‑disease therapies.
- Regulatory AgencyFDA
Granted full approval for Fayuvi, the first treatment for Type A Sanfilippo syndrome.
